Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
No benefit of heated abdominal chemotherapy in advanced colorectal cancer

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 604

Dr Francois Quenet - Regional Cancer Institute, Montpellier, France

Dr Quenet presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the PRODIGE 7 trial.

This was a phase III randomised trial in which patients with stage IV non-metastatic colorectal cancer received surgical treatment with or without heated oxaliplatin chemotherapy.

Dr Quenet describes the median overall survival at 64 months in both groups as equal, the time to disease recurrence as similar and that the addition of chemotherapy doubled the rate of complications.

For more on these results, watch his interview with ecancer, or read news coverage here.

View the slides here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation